The discovery and identification of a candidate proteomic biomarker of active tuberculosis

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Liu, Jiyan ^a   Jiang, Tingting ^a   Wei, Liliang ^b   Yang, Xiuyun ^c   Wang, Chong ^a   Zhang, Xing ^a   Xu, Dandan ^a   Chen, Zhongliang ^a   Yang, Fuquan ^d   Li, Ji Cheng ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b The Sixth Hospital of Shaoxing   (China)

^c Tongde Hospital of Zhejiang Provence Hangzhou   (China)

^d INSTITUTE OF BIOPHYSICS   (China)

Author keywords

Biomarker; Mass spectrometry; Proteomics; Tuberculosis

Indexed keywords

ALPHA E PREPROPROTEIN; BIOLOGICAL MARKER; FIBRINOGEN; FIBRINOGEN DEGRADATION PRODUCT; MEMBRANE PROTEIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CASE CONTROL STUDY; CATION EXCHANGE; COMPUTER PROGRAM; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOGEN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR WEIGHT; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN PURIFICATION; PROTEOMICS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; TRANSTHORACIC BIOPSY; TREATMENT RESPONSE; TUBERCULOSIS; UPREGULATION; ADOLESCENT; BLOOD; EARLY DIAGNOSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EARLY DIAGNOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY; TUBERCULOSIS; YOUNG ADULT;

EID: 84886398025     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-506     Document Type: Article

References (35)

1. Global tuberculosis report 2012 2012, http://www.who.int/tb/publications/global_report/gtbr12_main.pdf.
2. Kirschner DE, Young D, Flynn JL. Tuberculosis: global approaches to a global disease. Curr Opin Biotechnol 2010, 21:524-531. 10.1016/j.copbio.2010.06.002, 2943033, 20637596.
3. Marko-Varga G, Lindberg H, Löfdahl CG, Jönsson P, Hansson L, Dahlbäck M, Lindquist E, Johansson L, Foster M, Fehniger TE. Discovery of biomarker candidates within disease by protein profiling: principles and concepts. J Proteome Res 2005, 4:1200-1212. 10.1021/pr050122w, 16083270.
4. McNerney R, Maeurer M, Abubakar I, Marais B, McHugh TD, Ford N, Weyer K, Lawn S, Grobusch MP, Memish Z, Squire SB, Pantaleo G, Chakaya J, Casenghi M, Migliori GB, Mwaba P, Zijenah L, Hoelscher M, Cox H, Swaminathan S, Kim PS, Schito M, Harari A, Bates M, Schwank S, O'Grady J, Pletschette M, Ditui L, Atun R, Zumla A. Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J Infect Dis 2012, 205:147-158.
5. Ray S, Reddy PJ, Jain R, Gollapalli K, Moiyadi A, Srivastava S. Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead. Proteomics 2011, 11:2139-2161. 10.1002/pmic.201000460, 21548090.
6. Van Altena R, Duggirala S, Gröschel MI, van der Werf TS. Immunology in tuberculosis: challenges in monitoring of disease activity and identifying correlates of protection. Curr Pharm Des 2011, 17:2853-2862. 10.2174/138161211797470228, 21834760.
7. Pinto LM, Grenier J, Schumacher SG, Denkinger CM, Steingart KR, Pai M. Immunodiagnosis of tuberculosis: state of the art. Med Princ Pract 2012, 21:4-13. 10.1159/000331583, 22024473.
8. Cho WC. Proteomics technologies and challenges. Genomics Proteomics Bioinformatics 2007, 5:77-85. 10.1016/S1672-0229(07)60018-7, 17893073.
9. Yang SY, Xiao XY, Zhang WG, Zhang LJ, Zhang W, Zhou B, Chen G, He DC. Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer 2005, 5:83-89. 10.1186/1471-2407-5-83, 1183195, 16029516.
10. Cho WC. Research progress in SELDI-TOF MS and its clinical applications. Chin J Biotech 2006, 22:871-876.
11. Dursun E, Monari E, Cuoghi A, Bergamini S, Ozben B, Suleymanlar G, Tomasi A, Ozben T. Proteomic profiling during atherosclerosis progression using SELDI-TOF-MS: effect of darbepoetin treatment. Acta Histochem 2010, 112:432-443. 10.1016/j.acthis.2009.04.003, 19500820.
12. Pang RT, Poon TC, Chan KC, Lee NL, Chiu RW, Tong YK, Wong RM, Chim SS, Ngai SM, Sung JJ, Lo YM. Serum proteomic fingerprints of adult patients with severe acute respiratory syndrome. Clin Chem 2006, 52:421-429. 10.1373/clinchem.2005.061689, 16423906.
13. Hodgetts A, Levin M, Kroll JS, Langford PR. Biomarker discoveryin infectious diseases using SELDI. Future Microbiol 2007, 2:35-49. 10.2217/17460913.2.1.35, 17661674.
14. World Health Organization International Union Against Tuberculosis and Lung Disease; Royal Netherlands Tuberculosis Association: Revised international definitions in tuberculosis control. Int J Tuberc Lung Dis 2001, 5:213-215. World Health Organization.
15. Ligon LS, Hayden JD, Braunstein M. The ins and outs of Mycobacterium tuberculosis protein export. Tuberculosis (Edinb) 2012, 92:121-132. 10.1016/j.tube.2011.11.005, 3288827, 22192870.
16. Zhang J, Wu X, Shi L, Liang Y, Xie Z, Yang Y, Li Z, Liu C, Yang F. Diagnostic serum proteomic analysis in patients with active tuberculosis. Clin Chim Acta 2012, 413:883-887. 10.1016/j.cca.2012.01.036, 22330877.
17. Sinha S, Kosalai K, Arora S, Namane A, Sharma P, Gaikwad AN, Brodin P, Cole ST. Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics. Microbiology 2005, 151:2411-2419. 10.1099/mic.0.27799-0, 16000731.
18. Agranoff D, Fernandez-Reyes D, Papadopoulos MC, Rojas SA, Herbster M, Loosemore A, Tarelli E, Sheldon J, Schwenk A, Pollok R, Rayner CF, Krishna S. Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet 2006, 368:1012-1021. 10.1016/S0140-6736(06)69342-2, 16980117.
19. Liu Q, Chen X, Hu C, Zhang R, Yue J, Wu G, Li X, Wu Y, Wen F. Serum protein profiling of smear-positive and smear-negative pulmonary tuberculosis using SELDI-TOF mass spectrometry. Lung 2010, 188:15-23. 10.1007/s00408-009-9199-6, 20012079.
20. Zheng ZG, Yu HQ, Ling ZQ, Mou HZ, Deng HT, Mao WM. Comprehensive profiling of the low molecular weight proteins and peptides in weak cation exchange beads human serum retentate. Protein Pept Lett 2011, 18:498-506. 10.2174/092986611794927983, 21235487.
21. Song QB, Hu WG, Wang P, Yao Y, Zeng HZ. Identification of serum biomarkers for lung cancer using magnetic bead-based SELDI-TOF-MS. Acta Pharmacol Sin 2011, 32:1537-1542. 10.1038/aps.2011.137, 22019958.
22. Deng B, Dong Z, Liu Y, Wang C, Liu J, Wang C, Qu X. Effects of pretreatment protocols on human amniotic fluid protein profiling with SELDI-TOF MS using protein chips and magnetic beads. Clin Chim Acta 2010, 411:1051-1057. 10.1016/j.cca.2010.03.036, 20361951.
23. Robson SC, White NW, Aronson I, Woollgar R, Goodman H, Jacobs P. Acute-phase response and the hypercoagulable state in pulmonary tuberculosis. Br J Haematol 1996, 93:943-949. 10.1046/j.1365-2141.1996.d01-1722.x, 8703831.
24. Das PC, Allan AG, Woodfield DG, Cash JD. Fibrin degradation products in sera of normal subjects. Br Med J 1967, 4:718-720. 10.1136/bmj.4.5581.718, 1748968, 6060821.
25. Kwaan HC, Barlow GH. Nature and biological activities of degradation products of fibrinogen and fibrin. Annu Rev Med 1973, 24:335-344. 10.1146/annurev.me.24.020173.002003, 4575863.
26. Thomas DP, Niewiarowski S, Myers AR, Bloch KJ, Colman RW. A comparative study of four methods for detecting fibrinogen degradation products in patients with various diseases. N Engl J Med 1970, 283:663-668. 10.1056/NEJM197009242831301, 4247823.
27. Yatzidis H. Fibrin/fibrinogen degradation products in glomerulonephritis. Br Med J 1971, 3:767.
28. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005, 3:1894-1904. 10.1111/j.1538-7836.2005.01365.x, 16102057.
29. Turken O, Kunter E, Sezer M, Solmazgul E, Cerrahoglu K, Bozkanat E, Ozturk A, Ilvan A. Hemostatic changes in active pulmonary tuberculosis. Int J Tuberc Lung Dis 2002, 6:927-932.
30. Awodu OA, Ajayi IO, Famodu AA. Haemorheological variables in Nigeria pulmonary tuberculosis patients undergoing therapy. Clin Hemorheol Microcirc 2007, 36:267-275.
31. Sakamoto K, Geisel RE, Kim MJ, Wyatt BT, Sellers LB, Smiley ST, Cooper AM, Russell DG, Rhoades ER. Fibrinogen dimycolate regulates the cytotoxicity of mycobacterial trehalose but is not required for cell recruitment, cytokine response, or control of mycobacterial infection. Infect Immun 2010, 78:1004-1011. 10.1128/IAI.00451-09, 2825938, 20028811.
32. Hernández-Pando R, Arriaga AK, Panduro CA, Orozco EH, Larriva-Sahd J, Madrid-Marina V. The response of hepatic acute phase proteins during experimental pulmonary tuberculosis. Exp Mol Pathol 1998, 65:25-36. 10.1006/exmp.1998.2224, 9613924.
33. Magalhães V, Veiga-Malta I, Almeida MR, Baptista M, Ribeiro A, Trieu-Cuot P, Ferreira P. Interaction with human plasminogen system turns on proteolytic activity in Streptococcus agalactiae and enhances its virulence in a mouse model. Microbes Infect 2007, 9:1276-1284. 10.1016/j.micinf.2007.06.001, 17890121.
34. Rodríguez-Flores E, Campuzano J, Aguilar D, Hernández-Pando R, Espitia C. The response of the fibrinolytic system to mycobacteria infection. Tuberculosis (Edinb) 2012, 92:497-504. 10.1016/j.tube.2012.07.002, 22885283.
35. Monroy V, Amador A, Ruiz B, Espinoza-Cueto P, Xolalpa W, Mancilla R, Espitia C. Binding and activation of human plasminogen by Mycobacterium tuberculosis. Infect Immun 2000, 68:4327-4330. 10.1128/IAI.68.7.4327-4330.2000, 101759, 10858253.